January 22, 2026
Finance

UnitedHealth CEO Attributes US Health Care Cost Drivers Beyond Insurance, Commits to ACA Profit Rebates

Stephen Hemsley Identifies Hospital Pricing and Drug Costs as Primary Contributors to Rising Health Expenditures, Advocates Policy Reform

Summary

UnitedHealth Group's CEO, Stephen Hemsley, highlighted rising hospital prices, consolidation, specialty services, and prescription drug costs as major contributors to US health care spending increases, rather than insurers. He pledged to rebate profits from Affordable Care Act (ACA) exchange plans and proposed several policy changes to improve affordability and access.

Key Points

Hospital pricing, consolidation, specialty services, and prescription drugs are the main factors driving US health care spending growth, not insurance companies.
UnitedHealth plans to voluntarily rebate profits from Affordable Care Act exchange plans in 2023, although specific rebate details remain undisclosed.
The company's efforts include negotiating nearly $300 billion in discounts and saving $35 billion by reducing fraud and waste in 2022.
Hemsley advocates for policy reforms such as site-neutral payments, patent reform, limits on drug advertising, and standardization of ACA broker compensation to improve affordability and consumer choice.

In testimony before the US House Energy and Commerce Subcommittee on Health, Stephen Hemsley, chairman and CEO of UnitedHealth Group (NYSE: UNH), presented a detailed account of the main factors driving health care cost escalation in the United States. Hemsley emphasized that the chief contributors to rising expenditures are not insurance companies themselves, but rather the increasing prices set by hospitals, industry consolidation, growth in specialty services, and elevated prescription drug costs.

Hemsley, appearing alongside other health insurance executives from Cigna Group (NYSE: CI), Elevance Health Inc. (NYSE: ELV), and CVS Health Corp. (NYSE: CVS), addressed lawmakers on Thursday, outlining the complexities behind premium rate determinations. He explained that premiums are influenced predominantly by two variables: the volume of care accessed by patients and the pricing charged for that care. When both the utilization of care and the prices charged increase simultaneously, the escalations inevitably transfer to higher health coverage costs.

The CEO acknowledged that while the insurance industry plays a role in the overall health care system, the challenges extend beyond insurers. He stated, "The health care system is not as good as it should be," indicating a shared responsibility for its shortcomings. Nevertheless, Hemsley highlighted the insurers' efforts in containing costs through strategies such as negotiating discounts with providers, coordinating care to avoid unnecessary services, and focusing on preventive care to reduce hospital admissions and manage chronic diseases more effectively.

UnitedHealth serves a broad patient population, including nearly 10 million Medicare Advantage members, about 1 million enrollees in ACA marketplace plans, and Medicaid beneficiaries across 32 states. Though UnitedHealthcare holds a relatively small share of the individual ACA market, Hemsley made a significant commitment, announcing that the company will voluntarily forgo and rebate its profits from ACA exchange coverage for the current year. However, the testimony did not disclose specific details regarding the structure of these rebates or the expected financial impact on the company.

This voluntary rebate initiative was noted by Bloomberg as a potentially strategic response to ongoing criticism that UnitedHealth may be unduly benefiting from taxpayer-funded subsidies designed to support ACA enrollees.

In 2022 alone, UnitedHealth negotiated nearly $300 billion in provider discounts and identified approximately $35 billion in savings by curbing fraud and waste within the health care system. Hemsley underscored the effectiveness of value-based payment models and Medicare Advantage arrangements, which, according to him, provide improved patient outcomes at reduced costs, evidenced by fewer hospitalizations and better chronic illness management.

The hearing also reflected prior scrutiny of UnitedHealth’s Medicare Advantage practices. A Senate Judiciary Committee report had uncovered that the company employed assertive tactics to document patient diagnoses that elevated federal Medicare Advantage payments, turning this adjustment mechanism into a profit center in ways considered beyond its intended scope.

In addition to cost drivers, Hemsley proposed a series of policy reforms to facilitate greater affordability and consumer choice. Suggestions included adopting site-neutral payment methodologies to eliminate price disparities based on care settings, reforming patent rules to encourage competition, and imposing limits on direct-to-consumer pharmaceutical advertising. Enhancing consumer options in ACA plans was also advocated as a way to empower patients.

Hemsley further recommended that lawmakers standardize broker compensation structures within the ACA marketplace. Currently, variable commissions can incentivize brokers to steer consumers toward higher-paying plans, potentially misaligning with the consumers’ best interests. He highlighted that Medicare Advantage already employs standardized broker payments, which helps promote impartial plan selection. Aligning compensation in the ACA marketplace, he argued, would encourage decisions based on value, affordability, and accessibility rather than commission differentials.

Complementing these efforts, UnitedHealth announced in January the launch of a Rural Payment Acceleration Pilot designed to improve cash flow for rural hospitals by halving the payment collection duration from under 30 days to fewer than 15 days. This pilot program, spanning states like Oklahoma, Idaho, Minnesota, and Missouri, represents a six-month initiative targeting financial relief for independent rural providers.

Despite these initiatives, shares of UnitedHealth Group experienced a modest decrease of 0.5%, trading at $346.00 in premarket activity as of Thursday, a movement tracked by Benzinga Pro.

Risks
  • UnitedHealth's Medicare Advantage diagnosis coding practices have been scrutinized for potentially exceeding program intent, which could invite regulatory or legal challenges.
  • The voluntary rebate on ACA profits might impact UnitedHealth's financial performance, with unspecified financial implications.
  • Policy reforms proposed rely on Congressional action, which carries uncertainty regarding timing and implementation.
  • Ongoing public and regulatory scrutiny may affect insurer reputations and operational strategies, introducing potential market risks.
Disclosure
Education only / not financial advice
Search Articles
Category
Finance

Financial News

Ticker Sentiment
UNH - neutral
Related Articles
Oscar Health Targets Profitability in 2026 Following Challenging 2025

Oscar Health Inc. reported fourth-quarter revenue growth driven by expanding membership but faced in...

Becton Dickinson Faces Market Headwinds Amid Transition and Revised Earnings Projections

Becton Dickinson & Co. posted first-quarter earnings above analyst expectations but trimmed its fisc...

Quest Diagnostics Reports Strong Q4 Earnings and Raises Full-Year Guidance Driving Stock Higher

Quest Diagnostics posted fourth-quarter results surpassing both earnings and revenue expectations, d...

UBS Adjusts Tech Sector Outlook, Advocates Diversification Into Healthcare and Financials

UBS has revised its stance on the U.S. information technology sector from attractive to neutral, hig...

AstraZeneca Posts Solid Q4 Earnings, Shares Rally Near 52-Week High

AstraZeneca Plc reported fourth-quarter 2025 revenue of $15.50 billion, slightly above expectations,...

Evommune Shares Surge Amid Positive Phase 2a Data for Atopic Dermatitis Treatment

Evommune, Inc. witnessed a sharp increase in its stock price following the release of encouraging to...